Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced that its Lincomycin Hydrochloride Injection has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development is significant as it enhances the company’s product portfolio and strengthens its position in the pharmaceutical market, particularly for patients who cannot use penicillin for severe infections.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of generic drugs. The company is committed to providing high-quality and effective pharmaceutical solutions, with a market focus on addressing the needs of patients who require alternatives to standard treatments.
YTD Price Performance: -8.80%
Average Trading Volume: 14,342,383
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.15B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.